AngioGenex, Inc. (fka AGGX)

[e-ore]

I know this company is "dark" but there's a lot going on here. Memorial Sloan Kettering now a shareholder/investor. Deal in the works with The Trout Group. Their patented anti-cancer drug (that blocks tumor-associated new blood vessel formation and prevents tumor growth) also being considered as a treatment for macular degeneration, rheumatoid arthritis and diabetes. Their latest shareholder letter:

Dear AngioGenex Shareholder:
I am pleased to report that important progress was achieved by the Company in 2014. In particular, there has been a significant expansion of our knowledge of our potent anti-cancer drug, AGX51, a molecule that has the potential to have many advantages for use as an anti-cancer therapeutic. AGX51 is a small molecule that is easily and cheaply synthesized and, based on testing in a number of animal tumors, there is evidence that it has the potential to be used orally to treat many types of cancers. The potency and safety of this molecule was markedly increased this year by separating the two mirror-like entities (enantiomers) that constitute AGX51 into a highly active part (AGX51E-2) and relatively inactive part (AGX51E-1). The Company plans to bring the pure active form, AGX51E-2, into clinical testing in combination with a standard chemotherapeutic drug such as Taxol. Adding a second drug to treat cancer is common practice and it is one of the quickest and most effective ways to assess the anti-tumor effects of our drug. If results in man are similar to those observed in animals, it is expected that there will be a significant augmentation of the anti-cancer effect and a reduction in the toxicity of the chemotherapeutic.  
More recent research demonstrated that AGX51-E2 has the unusual and highly desirable property of blocking metastasis in extremely challenging animal models. Since metastasis is highly detrimental to cancer patients, it is our intention to test the ability of AGX51E-2 to block this process in man. We are greatly encouraged by the interest the clinical staff at the Memorial Sloan Kettering Cancer Center (MSKCC) has expressed in participating in these trials.
Progress was also achieved with our ocular program. Dr. Glenn Stoller, a member of our Ocular Scientific Advisory Board, reported significant advances in the Company’s ocular program with AGX51E-2 at the national Bascom-Palmer Symposium where he provided experimental results showing that AGX51E-2 is highly active in the animal model of human age related macular degeneration that predicted the clinical success of Lucentis (Genentech) and Eylea (Regeneron). AGX51-E2 was found more protective than Eylea in this model. The Company is pursuing opportunities for collaboration with an ocular company for the development of AGX51E-2 for the treatment of age related macular degeneration. Finally, we are pleased to report that in 2014 Memorial Sloan Kettering Cancer Center became an AngioGenex shareholder, and allowed our Chief Scientific Officer, Dr. Robert Benezra, to become a member of the AngioGenex Board of Directors.
Sincerely,
Richard Salvador
Chairman and President